DOCSLIB.ORG

Efficacy Analysis from Phase I Study of Lorvotuzumab

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Efficacy Analysis from Phase I Study of Lorvotuzumab ASH December 2010 Efficacy Analysis from Phase I Study of Lorvotuzumab Mertansine (IMGN901) Used as Monotherapy in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma Abstract # 1962 Chanan-Khan, A.1, Wolf, J.2, Garcia, J.3, Gharibo, M.4, Jagannath, S. 5, Manfredi, D.1 , Sher, T. 1, Martin, C.6, Weitman, S.7*, O’Leary, J.8*, Zildjian, S.8*, Bulger, E.8*, and Vescio, R.6 Roswell Park Cancer Institute, Buffalo, NY1; Medical Center of University of California San Francisco, San Francisco, CA2; Hospital Privado de Cordoba, Cordoba, Argentina3; Cancer Institute of New Jersey, New Brunswick, NJ4; St. Vincent’s Comprehensive Cancer Center, New York, NY5; Cedars-Sinai Samuel Oschin Cancer Center, Los Angeles, CA6; The University of Texas Health Science Center at San Antonio, San Antonio, TX7; ImmunoGen, Inc., Waltham, MA8; Background Objectives Results Continued • Lorvotuzumab mertansine (IMGN901) is a novel antibody-drug Primary Table 3: Treatment-Related Adverse Events Experienced by >10% of Patientsa Figure 3 : Treatment Duration (n=37) conjugate (ADC) composed of a CD56-targeting antibody with the • To determine the dose-limiting toxicity (DLT) and maximum tolerated dose maytansinoid, DM1, attached via a disulfide linker. (MTD), and the recommended phase II dose of single agent lorvotuzumab Lorvotuzumab mertansine dose (mg/m2) • CD56 is a neural cell adhesion molecule (NCAM) with surface mertansine. 40 60 75 90 112 140 Total Treatment Duration in Cycles expression in approximately 70% of multiple myeloma cases. Other Secondary n=3 n=3 n=3 n=3 n=19 n=6 n=37 tumor types expressing CD56 include small cell lung cancer, Merkel cell • To determine the qualitative and quantitative toxicities of single agent MR PR All MR carcinoma, ovarian cancer and neuroendocrine tumors. lorvotuzumab mertansine. Preferred Term All Gr Gr 3 All Gr Gr 3 All Gr Gr 3 All Gr Gr 3 All Gr Gr 3 All Gr Gr 3 Grades Grade 3 PR • In preclinical xenograft models, lorvotuzumab mertansine has • To evaluate the pharmacokinetics of single agent lorvotuzumab mertansine. Headache 1 2 5 4 12 demonstrated potent anti-tumor activity as monotherapy and in • To evaluate overall objective response rate and duration of response (DOR). MR * Fatigue 6 5 2 11 2 combination in several models of human malignancy including multiple • To assess time to progression, progression free survival and overall survival. myeloma. Neuropathyb 1 1 6 2 2 10 2 MR • In clinical trials assessing alternative dosing schedules, lorvotuzumab Methods AST increased 1 3 2 1 7 mertansine has been found to have an acceptable safety profile and has Constipation 1 2 3 6 demonstrated activity signals in a variety of CD56+ tumor types. Trial Design Diarrhea 5 1 6 • Reported here is the safety and activity of lorvotuzumab mertansine 37 Patients • Phase I multi-center, dose escalation study with 3+3 design. Nausea 1 2 2 5 when administered as single agent therapy to patients with CD56- • The MTD defined as the highest dose at which no more than 1/6 patients Anorexia 1 2 2 5 postiive multiple myeloma. experienced a DLT in cycle 1. • Once MTD was declared, up to 40 patients are to be enrolled (expansion Paraesthesia 4 1 5 Figure 1: Lorvotuzumab Mertansine Structure and Routes of phase). Asthenia 1 2 1 1 4 1 Intracellular Activation • Responses are assessed using the European Blood and Bone Marrow ALT increased 1 1 2 4 Transplantation (EMBT) criteria. Blood Uric Acid 0 102030405055 85 linker DM1 Treatment Scheme Increased 1 1 2 4 O Lorvotuzumab Number of Weeks S S CH3 Humanized IgG1 antibody • Lorvotuzumab mertansine is administered as an intravenous (IV) infusion Myalgia 1 2 1 4 LorvotuzumabhuN901 HN NO • 40 60 75 90 112 140 O CH3 once weekly for two weeks every three weeks. 2 H3C O Conjugated to DM1 Dose Limiting Criteria a. Patients who experienced the same coded event more than once are counted only once under that coded event. (Dose Cohort mg/m ) CH3 O b. Neuropathy includes sensory neuropathy and peripheral neuropathy. Cl N O • Derivative of maytansine • Any of the following that are at least possibly related to lorvotuzumab CH3 • Antimitotic – inhibits tubulin Minimal Response (MR) H3CO mertansine: There were no treatment-related Grade 4 adverse events (AE). The grade 3 treatment-related AEs that are not included in CH3 O polymerization • Grade 4 neutropenia ≥ 5 days. this table (experienced by less than 10% of patients) are neutropenia (1 patient at 112 mg/m2), areflexia (1 patient at 140 Partial Response (PR) O Attached to antibody via a * Patient ongoing at time of data cut off. N • • Grade 3 or greater febrile neutropenia or Grade 4 thrombocytopenia. 2 2 H CO HO H mg/m ) and renal failure (1 patient at 140 mg/m ). Renal failure and fatigue were deemed the dose-limiting toxicities. CH 3 disulfide linker 3 • Grade 3 or 4 non-hematological toxicity (excluding alopecia or sub- n optimally treated nausea, vomiting or diarrhea). Figure 4: Case Descriptions n ~ 3.5 (DM1 is ~ 1.8% by weight of Mab) • Any other lorvotuzumab mertansine-related toxicity deemed dose limiting. Eligibility Case Description: Patient 0226 Monoclonal Protein (0232) Case Description: Patient 0244 Major Inclusion Criteria 5 450 • 62 year old female with stage III relapsed multiple myeloma with • 57 year old male with stage III relapsed/refractory multiple myeloma Bind to antigen • Diagnosed of multiple myeloma (CD56-positive) based on standard criteria. 400 multiple bone lesions. 4 on cell surface Internalization • Age ≥ 18 years and ECOG performance status of 0-2. 350 with multiple bone lesions. via endocytosis • One prior treatment with bortezomib, doxorubicin and 300 • Multiple radiation therapies and 6 prior lines of chemotherapy (most • Standard oncology phase I laboratory inclusion criteria. 3 Disulfide thalidomide (partial response). Progressed 3 months later. 250 recent treatment with cyclophosphamide). Progressive disease cleavage Major Exclusion Criteria 2 2 200 Tubulin • Treatment at 140 mg/m . The patient received 26 cycles of within 8 months of last therapy. DM1 • Significant residual neurological or cardiac toxicity from prior therapy. 150 Serum g/dL 2 Traffic to lorvotuzumab mertansine, and achieved partial response 1 100 Urine mg/24hr • Treatment at 112 mg/m . The patient has received 6 cycles of Lysosome • History of significant underlying cardiac disorders. Lysine-LINK-DM1 DM1 (duration of response 13 months) with a reduction of serum M 50 treatment and has achieved minimal response with a 42% reduction Disulfide • History of multiple sclerosis or other demyelinating disease or any CNS injury 0 0 Cleavage Tubulin component of 52%. in serum M component. Cancer Cell with residual neurological deficit. Jul-09 Oct-09 Jan-10 May-10 Aug-10 Degradation of • Patient decision to discontinue treatment. • Patient remains active on study. MAb in lysosome • Previous sensitivity to monoclonal antibody therapy. Bystander Serum Urine Cancer Cell • Prior malignancy within the last 3 years. Monoclonal Protein (0226) Monoclonal Protein (0244) Erickson et al, 2006 5 450 5 450 Results 400 Case Description: Patient 0232 400 4 350 • 51 year old male with stage III relapsed multiple myeloma with bone and 4 350 Lorvotuzumab mertansine binds with high affinity to CD56 expressed on the 300 soft tissue lesions. 300 surface of tumor cells. The conjugate is then internalized. Inside the cell, Table 1: Cohort Size (n=37) 3 250 3 250 • One prior treatment with bortezomib, doxorubicin and thalidomide DM1 is released by cleavage of the disulfide linker. The DM1 disrupts tubulin 2 200 2 200 Dose (mg/m2) 40 60 75 90 112 140 Total 150 (partial response). Progressed ~10 months later. 150 polymerization and microtubule assembly. Serum g/dL Serum g/dL 100 Urine mg/24hr 2 100 1 • Treatment at 112 mg/m . The patient received 10 cycles of lorvotuzumab 1 mg/24hr Urine Patients (n) 33 3 319637 50 50 Figure 2: Dose Response of Lorvotuzumab Mertansine in Myeloma mertansine, and achieved partial response with a 46% decrease in 0 0 0 0 Xenograft Models serum M component. Table 2: Patient Demographics and Disease Characteristics (n=37) Jun-08 Dec-08 Jul-09 Jan-10 Aug-10 May-10 Jul-10 Aug-10 Sep-10 Oct-10 • Investigator decision to discontinue treatment due to a slight decrease in response and increase in neuropathy (grade 2). NCI-H929 MOLP-8 Median Age, years (range) 61 (39-85) Serum Urine Serum Urine 2000 2000 ) 3 ) 3 Gender, n (%) 1500 1500 Table 4: Pharmacokinetics (n=37) Conclusions Male 21 (57) • The MTD has been identified as 112 mg/m2 and is being explored for activity in a less 1000 1000 Female 16 (43) Dose 40 60 75 90 112 140 heavily pretreated patient population (6 or fewer prior treatments) in the expansion phase. (mg/m2) ECOG Performance Status at Screening, n (%) • Preliminary pharmacokinetic data suggests that exposure and maximum plasma 500 500 Plasma Exposure (AUC) observed 0 23 (62) concentration of lorvotuzumab mertansine increase with increasing dose. Elimination half life MeanTumor Volume (mm Mean tumor volume (mm Number 4000 remains similar at all dose levels. 0 0 3 3 3 3 19 6 20 40 60 80 100 120 15 25 35 45 55 65 1 13 (35) patients (n) • Lorvotuzumab mertansine was generally well tolerated in this heavily pretreated population Days after Tumor Inoculation Days after Tumor Inoculation 2 1 (3) of patients. There was no clinically significant myelosuppression. Mild-to-moderate PBS PBS 3000 headache, fatigue and neuropathy were the most commonly reported treatment-related IMGN901, 7 mg/kg qw x2 IMGN901, 7 mg/kg qw x2 Race, n (%) Cmax 32.8 ± 53.3 ± 42.9 ± 49.3 ± 55.1 ± 81.5 ± IMGN901, 13 mg/kg qw x2 IMGN901, 13 mg/kg qw x2 adverse events.
Load more

Recommended publications
  • The New Generation of Antibody Therapeutics: Current Status and Future Prospects
    Expert Intelligence for Better Decisions The New Generation of Antibody Therapeutics: Current Status and Future Prospects K. John Morrow, Jr., PhD Using This Document A navigation bar containing links to the Table of Contents, a Search feature, Insight Pharma Reports are interactive Previous/Next page arrows, and a Return button is anchored at the bottom of electronic documents which offer many each page. of the features of Web sites, including Hyperlinks throughout the document are designated by blue, underlined text. navigation, search, bookmarks, download Hyperlinks on the Index page are also rendered as blue text, and will navigate you options, and additional layered content. to a company’s Web site. Table of Contents listings are hyperlinked and will navigate you directly to that specific content, Table or Figure. Reports are also available Figures and Tables found within the document are available for download by clicking on a selected Figure or the title of a Table. The document will open in in printed format your browser. To order copies of this report, customized for l For Figures, which are in JPEG format, right-click to save to your desktop your organization, contact: l For Tables, which are in PDF format, save directly from your browser Rose LaRaia P 781-972-5444 E [email protected] References can be accessed by clicking directly on the Reference number. There is also a References page at the end of the document. Next Page Return This button will return you to a previously visited, non-sequential page Access the Table of Contents Previous Page Search the Report Insight Pharma Reports Web site Visit our site to research additional Report titles Contents Search i www.InsightPharmaReports.com Insight Pharma Reports Single User License This License permits only the Licensee with individual access to the report.
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • ADC (Antibody-Drug Conjugates
    Antibody-drug Conjugate All-sided compounds and intermediates to support novel biotherapeutics research and technology Antibody- drug Conjugate ADC Products Based on advanced technology and years of experience, Creative Biolabs offers a variety of customized ADC, linker-Toxin ANTIBODY-DRUG products, ADCs cytotoxin, ADCs linkers, Anti-drug Abs and Anti-Ab ADCs for your CONJUGATE ADC projects and promote your progress in ADC development. Comprehensive one-stop-shop for all aspects in ADC research and development Creative Biolabs Established in 2004, Creative Biolabs is a world-renowned service provider for antibody-drug conjugate (ADC) service and products. After years of pursuit for perfection, Creative BioLabs has established leadership in targeted immunotherapy and ADC development. Outline 01.Customized ADCs 02.Linker-Toxin 03.ADCs Cytotoxin 04.ADCs Linker 05.Anti-drug Abs Creative Biolabs provides a 06.Anti-Ab ADCs full range of ADC products to help your 07.Contact us ADC development . Antibody- drug Conjugate CUSTOMIZED ADCS Creative Biolabs offers a variety of customarily prepared ADC products to serve the course of ADC development and evaluation. Taken advantage of our large inventory of therapeutic antibodies, our scientists help create the custom ADC products by conjugating therapeutic antibodies against cancer surface antigens with different drug-linker complexes. APPLICATION ADCs have created a new paradigm for novel anticancer drug development. With both the specificity of the large-molecule monoclonal antibody and the potency of the small molecule cytotoxic drug, ADCs have tremendous potential to be part of the future of cancer precision medicine as well as cancer combination therapies. Customized ADCs Cat.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Monoclonal Antibodies in Myeloma
    Monoclonal Antibodies in Myeloma Pia Sondergeld, PhD, Niels W. C. J. van de Donk, MD, PhD, Paul G. Richardson, MD, and Torben Plesner, MD Dr Sondergeld is a medical student at the Abstract: The development of monoclonal antibodies (mAbs) for University of Giessen in Giessen, Germany. the treatment of disease goes back to the vision of Paul Ehrlich in Dr van de Donk is a hematologist in the the late 19th century; however, the first successful treatment with department of hematology at the VU a mAb was not until 1982, in a lymphoma patient. In multiple University Medical Center in Amsterdam, The Netherlands. Dr Richardson is the R.J. myeloma, mAbs are a very recent and exciting addition to the Corman Professor of Medicine at Harvard therapeutic armamentarium. The incorporation of mAbs into Medical School, and clinical program current treatment strategies is hoped to enable more effective and leader and director of clinical research targeted treatment, resulting in improved outcomes for patients. at the Jerome Lipper Myeloma Center, A number of targets have been identified, including molecules division of hematologic malignancy, depart- on the surface of the myeloma cell and components of the bone ment of medical oncology, Dana-Farber Cancer Institute in Boston, MA. Dr Plesner marrow microenvironment. Our review focuses on a small number is a professor of hematology at the Univer- of promising mAbs directed against molecules on the surface of sity of Southern Denmark and a consultant myeloma cells, including CS1 (elotuzumab), CD38 (daratumumab, in the department of hematology at Vejle SAR650984, MOR03087), CD56 (lorvotuzumab mertansine), and Hospital in Vejle, Denmark.
    [Show full text]
  • Immunotherapy in Multiple Myeloma
    116 Review Article Immunotherapy in multiple myeloma Irene M. Hutchins, Levanto G. Schachter, Anuj K. Mahindra Scripps Clinic, La Jolla, CA, USA Contributions: (I) Conception and design: IM Hutchins; (II) Administrative support: None; (III) Provision of study material or patients: None; (IV) Collection and assembly of data: None; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Irene M. Hutchins, MD. Scripps Clinic, 10666 N. Torrey Pines Rd. MS312, La Jolla, CA 92037, USA. Email: [email protected]. Abstract: Therapeutic approaches in multiple myeloma (MM) are increasingly focused on restoring antitumor immunity. Immunomodulators have a variety of effects on the immune microenvironment, and are frequently incorporated into multidrug regimens. The monoclonal antibodies daratumumab and elotuzumab have been granted accelerated approval for use in the relapsed or refractory setting, and several other antibodies including immune checkpoint inhibitors are currently being evaluated for the treatment of MM. Antimyeloma vaccines have been developed, and may be useful in maintaining remission. The role of allogeneic stem cell transplantation continues to be an area of active research, as reduced intensity conditioning (RIC) regimens have significantly decreased treatment-related complications. Other immunotherapeutic approaches in development include marrow infiltrating lymphocytes, T cell receptor modified T cells (TCRts), and chimeric antigen receptor (CAR) T cells. Here we review the existing data on immunotherapy in MM, and discuss some promising areas of research which may impact the future of myeloma therapy. Keywords: Antibodies; monoclonal; immunotherapy; multiple myeloma (MM); receptors; antigen; T-cell; stem cell transplantation Submitted Nov 23, 2016.
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    INN Working Document 05.179 Update 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int ) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Ep 3321281 A1
    (19) TZZ¥¥ _ __T (11) EP 3 321 281 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 16.05.2018 Bulletin 2018/20 C07K 14/79 (2006.01) A61K 38/40 (2006.01) A61K 38/00 (2006.01) A61K 38/17 (2006.01) (2006.01) (2006.01) (21) Application number: 17192980.5 A61K 39/395 A61K 39/44 C07K 16/18 (2006.01) (22) Date of filing: 03.08.2012 (84) Designated Contracting States: • TIAN, Mei Mei AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Coquitlam, BC V3J 7E6 (CA) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • VITALIS, Timothy PL PT RO RS SE SI SK SM TR Vancouver, BC V6Z 2N1 (CA) (30) Priority: 05.08.2011 US 201161515792 P (74) Representative: Gowshall, Jonathan Vallance Forresters IP LLP (62) Document number(s) of the earlier application(s) in Skygarden accordance with Art. 76 EPC: Erika-Mann-Strasse 11 12746240.6 / 2 739 649 80636 München (DE) (71) Applicant: biOasis Technologies Inc Remarks: Richmond BC V6X 2W8 (CA) •This application was filed on 25.09.2017 as a divisional application to the application mentioned (72) Inventors: under INID code 62. • JEFFERIES, Wilfred •Claims filed after the date of receipt of the divisional South Surrey, BC V4A 2V5 (CA) application (Rule 68(4) EPC). (54) P97 FRAGMENTS WITH TRANSFER ACTIVITY (57) The present invention is related to fragments of duction of the melanotransferrin fragment conjugated to human melanotransferrin (p97). In particular, this inven- a therapeutic or diagnostic agent to a subject.
    [Show full text]
  • Antibody–Drug Conjugates for Cancer Therapy
    molecules Review Antibody–Drug Conjugates for Cancer Therapy Umbreen Hafeez 1,2,3, Sagun Parakh 1,2,3 , Hui K. Gan 1,2,3,4 and Andrew M. Scott 1,3,4,5,* 1 Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, VIC 3084, Australia; [email protected] (U.H.); [email protected] (S.P.); [email protected] (H.K.G.) 2 Department of Medical Oncology, Olivia Newton-John Cancer and Wellness Centre, Austin Health, Melbourne, VIC 3084, Australia 3 School of Cancer Medicine, La Trobe University, Melbourne, VIC 3084, Australia 4 Department of Medicine, University of Melbourne, Melbourne, VIC 3084, Australia 5 Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC 3084, Australia * Correspondence: [email protected]; Tel.: +61-39496-5000 Academic Editor: João Paulo C. Tomé Received: 14 August 2020; Accepted: 13 October 2020; Published: 16 October 2020 Abstract: Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. ADCs provide a unique opportunity to deliver drugs to tumor cells while minimizing toxicity to normal tissue, achieving wider therapeutic windows and enhanced pharmacokinetic/pharmacodynamic properties. To date, nine ADCs have been approved by the FDA and more than 80 ADCs are under clinical development worldwide. In this paper, we provide an overview of the biology and chemistry of each component of ADC design. We briefly discuss the clinical experience with approved ADCs and the various pathways involved in ADC resistance.
    [Show full text]
  • INN Working Document 05.179 Update 2011
    INN Working Document 05.179 Update 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Essential Medicines and Pharmaceutical Policies (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2011 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • IMSN Letter on Antibody-Drug Conjugates 2015 03 23
    March 23, 2015 Dr Raffaella G. Balocco Mattavelli Manager of the International Nonproprietary Name (INN) Programme Quality Assurance and Safety: Medicines Department of Essential Medicines and Health Products (EMP) World Health Organization CH 1211 GENEVA 27 - SWITZERLAND Dear Dr Mattavelli: This letter is in regards to nomenclature of antibody-drug conjugates • As you are aware, during the clinical trials of trastuzumab emtansine, deaths resulting from confusion with trastuzumab drew attention to the risks associated with International nonproprietary names (INNs) of such cytotoxic substances with a common part. • The International Medication Safety Network (IMSN) was quickly alerted to these risks, and proposed that a new substitute INN should be examined by the WHO INN Programme, the only international body in charge eventually changing an INN. A proposal for substitution of trastuzumab emtansine is expected to be submitted by Canadian Healthcare authorities according to the international procedure. • By studying the possibilities of preventing this type of error, the IMSN found that these risks of confusion apply to all antibody-drug conjugates. The IMSN is therefore calling on the WHO INN Programme to identify nomenclature that will reduce their potentially fatal similarities and define clear rules to help recognize products that include different substances, in order to make them safer. If necessary, the IMSN is ready to contribute to the assessment of this risk reduction and prevention strategy, essential but belonging to the sole authority of the WHO INN Programme. The trastuzumab emtansine case. In 2013 the confusion between trastuzumab and trastuzumab emtansine drew attention to the risks associated with the INNs of cytotoxic compounds with a common part.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]